> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Common Violations in Recent DTC Letters from FDA
- URL: https://www.fdaweb.com/common-violations-in-recent-dtc-letters-from-fda/
- Published: 2026-02-13T12:00:00.000Z
- Updated: 2026-09-14T13:33:45.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160668

FDA is supporting renewed scrutiny of direct-to-consumer (DTC) television advertising as CDER Office of Prescription Drug Promotion (OPDP) is stepping up enforcement activity based on recent letters to industry. OPDP has issued seven untitled letters so far in 2026 to companies, including Janssen, Sobi, Novo Nordisk, and argenx, signaling continued oversight of broadcast pharmaceutical promotions.

While the letters do not articulate a single overarching policy shift, they cluster around two recurring themes: what the agency views as oversimplification of drug administration and promotional taglines that regulators believe stretch beyond the clinical data supporting a product, according to a Sheppard law [post](https://www.sheppard.com/insights/blogs/what-to-watch-opdp-off-to-a-roaring-2026?ref=fdaweb.com) from attorney [Dominick P. DiSabatino](https://www.sheppard.com/people/dominick-disabatino?ref=fdaweb.com).

In letters concerning argenx’s Vyvgart Hytrulo, OPDP took issue with how the ads portrayed the drug’s administration process. According to the agency, the commercials reduced complex injection protocols to brief time-based soundbites and paired those claims with “on-the-go” visuals that could understate the practical realities or risks associated with treatment.

Regulators cautioned that distilling administration details into simplified messaging may mislead patients if it glosses over nuances contained in the product’s Instructions for Use, the post says. The letters suggest that when broadcast ads emphasize convenience without sufficient context, OPDP may regard the presentation as misleading, noting that the line between clarity and oversimplification has long been a friction point in DTC advertising, particularly for specialty biologics requiring infusions or multi-step injections.

The agency also scrutinized aspirational branding language. For example, the post notes Sobi’s promotion of Vonjo and OPDP objecting to the tagline “turn the page,” concluding that the metaphor implied a broad improvement in health-related quality of life not fully supported by clinical trial endpoints cited in the product’s labeling.

Similarly, in a letter to Novo Nordisk addressing ads for Wegovy, OPDP challenged the slogan “Live Lighter.” The agency said that, taken together with other elements of the ad, the phrase could suggest a clinical advancement over other approved GLP-1 therapies or imply benefits beyond those demonstrated in the labeling. In particular, regulators focused on language such as “now you can,” arguing that it could convey superiority or novel clinical benefit not substantiated by the evidence reviewed during approval, according to the post.

These letters also reflect a continued emphasis on the “net impression” standard in FDA advertising enforcement — meaning regulators evaluate not only specific claims, but also the overall audio-visual tone and consumer takeaway, the post says.

The early volume of such letters in 2026 suggests OPDP remains actively engaged in monitoring broadcast promotions, it adds.